In particular, our results have implications for disease in the following contexts: 1) diseases in which HSF1 activation is a hallmark (such as cancer), 2) diseases characterised by increased FN deposition by unknown mechanisms (such as diabetes) and 3), diseases in which GA or other N-terminal inhibitors known to activate HSF1 are to be used therapeutically. Here, FN1 is linked to cancer.